United States Genomics Market Overview
Base Year: 2023
Historical Years: 2018-2023
Forecast Years: 2024-2032
Market Growth Rate: 19.60% (2024-2032)
According to the latest report by IMARC Group, The United States genomics market size is projected to grow at a CAGR of 19.60% from 2024 to 2032. The market is driven by rapid advancements in sequencing technologies and the decreasing cost of genomic sequencing.
United States Genomics Industry Trends and Drivers:
Over the past two decades, the development of next-generation sequencing (NGS) technologies has revolutionized the field of genomics by enabling the rapid, accurate, and cost-effective sequencing of entire genomes. These advancements have significantly lowered the cost of sequencing a human genome from billions of dollars to less than $1,000, making genomic data more accessible to researchers, healthcare providers, and patients. This democratization of genomic information has spurred a surge in genomic research, personalized medicine, and consumer genomics. Researchers can now conduct large-scale genomic studies, leading to the discovery of new genetic markers and the development of targeted therapies for various diseases. In the clinical setting, affordable genomic sequencing has paved the way for precision medicine, where treatments and preventive strategies are tailored to the individual genetic profiles of patients, improving outcomes, and reducing adverse effects. Another crucial factor driving the United States genomics market is the growing integration of genomics into healthcare and the increasing demand for personalized medicine. The rise of precision medicine, which focuses on customizing healthcare based on an individual’s genetic makeup, lifestyle, and environment, is fundamentally altering the landscape of medical treatment. Genomic data is now being used to develop personalized treatment plans for a range of conditions, including cancer, cardiovascular diseases, and rare genetic disorders. For instance, in oncology, genomic profiling of tumors enables the identification of specific genetic mutations driving cancer growth, allowing for the selection of targeted therapies that are more effective and less toxic than traditional treatments. Additionally, the application of genomics in prenatal and newborn screening, pharmacogenomics, and the diagnosis of rare diseases is expanding, driven by the promise of more accurate and early detection, as well as the potential to prevent or mitigate the impact of genetic disorders.
The increasing adoption of genomics in healthcare is supported by significant investments from both the public and private sectors. The National Institutes of Health (NIH) and other government agencies have launched large-scale initiatives, such as the All of Us Research Program, aimed at gathering genetic data from diverse populations to advance our understanding of health and disease. These programs not only drive scientific discovery but also build infrastructure and create databases that facilitate further research and clinical applications. In the private sector, pharmaceutical and biotechnology companies are investing heavily in genomics to accelerate drug discovery and development. Collaborations between industry, academia, and healthcare providers are fostering innovation and translating genomic research into clinical practice. Regulatory support and the establishment of ethical guidelines also play a vital role in driving the genomics market. The U.S. Food and Drug Administration (FDA) and other regulatory bodies are working to create frameworks that ensure the safe and effective use of genomic technologies in healthcare.
United States Genomics Industry Segmentation:
The report has segmented the market into the following categories:
Component Insights:
- Products
- Instruments and Software
- Consumables and Reagents
- Services
- Core Genomics Services
- NGS-Based Services
- Biomarker Translation Services
- Computational Services
- Others
Technology Insights:
- Sequencing
- Microarray
- Polymerase Chain Reaction
- Nucleic Acid Extraction and Purification
- Others
Application Insights:
- Functional Genomics
- Epigenomics
- Biomarkers Discovery
- Pathway Analysis
- Others
End User Insights:
- Research Centers
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Others
Regional Insights:
- Northeast
- Midwest
- South
- West
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Key highlights of the Report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Ask analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=20477&flag=F
Browse more research report:
| United States Luxury Goods Market |
| United States Platelet Rich Plasma Market |
| United States Healthcare Cloud Computing Market |
| United States Office Furniture Market |
| United States Robotics Market |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145